MX2022003585A - Metodos para tratar hiperfenilalaninemia. - Google Patents
Metodos para tratar hiperfenilalaninemia.Info
- Publication number
- MX2022003585A MX2022003585A MX2022003585A MX2022003585A MX2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hyperphenylalaninemia
- treat
- sepiapterin
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905720P | 2019-09-25 | 2019-09-25 | |
| PCT/US2020/052871 WO2021062264A1 (en) | 2019-09-25 | 2020-09-25 | Methods for treating hyperphenylalaninemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003585A true MX2022003585A (es) | 2022-04-19 |
Family
ID=72827023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003585A MX2022003585A (es) | 2019-09-25 | 2020-09-25 | Metodos para tratar hiperfenilalaninemia. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220362249A1 (https=) |
| EP (1) | EP4034122B1 (https=) |
| JP (2) | JP7661315B2 (https=) |
| KR (1) | KR20220070477A (https=) |
| CN (1) | CN114650825A (https=) |
| BR (1) | BR112022003719A2 (https=) |
| CA (1) | CA3150003A1 (https=) |
| DK (1) | DK4034122T3 (https=) |
| ES (1) | ES3041002T3 (https=) |
| FI (1) | FI4034122T3 (https=) |
| HR (1) | HRP20251268T1 (https=) |
| HU (1) | HUE073483T2 (https=) |
| IL (1) | IL291565B1 (https=) |
| JO (1) | JOP20220042A1 (https=) |
| LT (1) | LT4034122T (https=) |
| MX (1) | MX2022003585A (https=) |
| PL (1) | PL4034122T3 (https=) |
| PT (1) | PT4034122T (https=) |
| RS (1) | RS67295B1 (https=) |
| SI (1) | SI4034122T1 (https=) |
| SM (1) | SMT202500493T1 (https=) |
| WO (1) | WO2021062264A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) * | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| ES2586945T3 (es) * | 2014-03-31 | 2016-10-19 | Vasopharm Gmbh | Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) * | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
-
2020
- 2020-09-24 IL IL291565A patent/IL291565B1/en unknown
- 2020-09-25 HR HRP20251268TT patent/HRP20251268T1/hr unknown
- 2020-09-25 EP EP20789788.5A patent/EP4034122B1/en active Active
- 2020-09-25 SM SM20250493T patent/SMT202500493T1/it unknown
- 2020-09-25 PL PL20789788.5T patent/PL4034122T3/pl unknown
- 2020-09-25 US US17/764,003 patent/US20220362249A1/en active Pending
- 2020-09-25 SI SI202030677T patent/SI4034122T1/sl unknown
- 2020-09-25 RS RS20250917A patent/RS67295B1/sr unknown
- 2020-09-25 JP JP2022518780A patent/JP7661315B2/ja active Active
- 2020-09-25 CN CN202080067020.4A patent/CN114650825A/zh active Pending
- 2020-09-25 PT PT207897885T patent/PT4034122T/pt unknown
- 2020-09-25 HU HUE20789788A patent/HUE073483T2/hu unknown
- 2020-09-25 MX MX2022003585A patent/MX2022003585A/es unknown
- 2020-09-25 FI FIEP20789788.5T patent/FI4034122T3/fi active
- 2020-09-25 CA CA3150003A patent/CA3150003A1/en active Pending
- 2020-09-25 LT LTEPPCT/US2020/052871T patent/LT4034122T/lt unknown
- 2020-09-25 BR BR112022003719A patent/BR112022003719A2/pt unknown
- 2020-09-25 DK DK20789788.5T patent/DK4034122T3/da active
- 2020-09-25 ES ES20789788T patent/ES3041002T3/es active Active
- 2020-09-25 WO PCT/US2020/052871 patent/WO2021062264A1/en not_active Ceased
- 2020-09-25 KR KR1020227013671A patent/KR20220070477A/ko active Pending
-
2022
- 2022-02-22 JO JOP/2022/0042A patent/JOP20220042A1/ar unknown
-
2025
- 2025-04-02 JP JP2025061214A patent/JP2025111476A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202500493T1 (it) | 2026-01-12 |
| SI4034122T1 (sl) | 2025-12-31 |
| IL291565B1 (en) | 2026-04-01 |
| AU2020353676A1 (en) | 2022-04-14 |
| HUE073483T2 (hu) | 2026-01-28 |
| FI4034122T3 (fi) | 2025-10-08 |
| IL291565A (en) | 2022-05-01 |
| CA3150003A1 (en) | 2021-04-01 |
| DK4034122T3 (da) | 2025-09-15 |
| LT4034122T (lt) | 2025-11-10 |
| JP2025111476A (ja) | 2025-07-30 |
| JP2022549834A (ja) | 2022-11-29 |
| JOP20220042A1 (ar) | 2023-01-30 |
| HRP20251268T1 (hr) | 2025-12-05 |
| PT4034122T (pt) | 2025-09-18 |
| WO2021062264A1 (en) | 2021-04-01 |
| CN114650825A (zh) | 2022-06-21 |
| EP4034122A1 (en) | 2022-08-03 |
| ES3041002T3 (en) | 2025-11-06 |
| JP7661315B2 (ja) | 2025-04-14 |
| US20220362249A1 (en) | 2022-11-17 |
| EP4034122B1 (en) | 2025-08-13 |
| RS67295B1 (sr) | 2025-11-28 |
| BR112022003719A2 (pt) | 2022-05-31 |
| KR20220070477A (ko) | 2022-05-31 |
| PL4034122T3 (pl) | 2026-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003585A (es) | Metodos para tratar hiperfenilalaninemia. | |
| CY1123833T1 (el) | Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| CL2019000485A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. | |
| MX2018015630A (es) | Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurogenerativos. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| WO2016100261A3 (en) | Method of treating cancer with cgamp or cgasmp | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| ECSP109889A (es) | Composiciones terapeuticas y usos de las mismas | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
| MX2018003023A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
| ECSP22016180A (es) | Proteínas de fusión terapéuticas | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| AR106559A1 (es) | Suspensión acuosa para administración oral y método para su preparación | |
| CY1124851T1 (el) | Νεες ενωσεις | |
| AR094241A1 (es) | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos |